Search results (1345)
« Back to PublicationsCMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Milotay G. et al, (2025), Nature Medicine
Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1
Agarwal P. et al, (2025), Nature
Genome-wide association study of somatic GATA1s mutations in newborns with Down Syndrome.
Li Y. et al, (2025), Blood Adv
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
Hosseini A. et al, (2025), Nature
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Daver NG. et al, (2025), Blood Journal
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML.
Wang Z. et al, (2025), Blood
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Plummer R. et al, (2025), Cell Rep Med
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3
Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.
Dummer R. et al, (2025), Clin Cancer Res
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2025), Nat Commun, 16
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Zeidner JF. et al, (2025), Blood
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Lawson NM. et al, (2025)
Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.
Di Giovannantonio M. et al, (2025), Cell Genom, 5
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Harrington K. et al, (2025), Future Oncol, 21, 195 - 200
The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.
Greene J. et al, (2025), Cancer Control, 32